Off-label, some of them (vemurafenib, dabrafenib, trametinib, and cobimetinib) can be used in Langerhans cell histiocytosis (LCH) in children with the BRAFV600E mutation [3,4,5], a rare disease characterized by abnormal macrophage proliferation and granulomatous lesions composed of CD1a+CD207+ histiocytes [6]. This evidence concerns the gene CD1A and Langerhans cell histiocytosis.